October 27, 2026
Burning Rock Presents STELLA Clinical Validation at ESMO 2026, Exploring an Adjunctive Approach to Differentiating Benign and Malignant Breast Lesions

MADRID, Spain, October 27, 2026 — Burning Rock Biotech Limited (“Burning Rock”) and its clinical collaborators from Jiangsu Province Hospital and the Affiliated Hospital of Qingdao University presented clinical validation results (Poster 2458P) at the European Society for Medical Oncology (ESMO) Congress 2026, exploring STELLA’s potential to support the differentiation of benign and malignant breast lesions as an adjunct to breast imaging.


Accurate differentiation of benign and malignant breast lesions is essential for personalized clinical management. To evaluate the role of liquid biopsy in this setting, Burning Rock and its clinical collaborators conducted the prospective PERCEIVE-BREAST study. The study used Burning Rock’s SPIRAL platform to detect methylation signals and applied STELLA, a tumor-agnostic, DNA methylation-based algorithm, to quantify circulating tumor DNA (ctDNA) levels and evaluate its clinical performance in supporting the differential diagnosis of breast lesions.


Blood samples were prospectively collected before any anti-tumor therapy. The analysis included 516 patients: 395 with invasive breast cancer, 15 with in situ carcinoma, and 106 with benign breast lesions. The study evaluated overall sensitivity and specificity, with further analyses by clinical stage, molecular subtype, and imaging classification.


STELLA achieved 65.9% overall sensitivity and 97.2% specificity. Sensitivity increased with disease stage, reaching 32.7%, 77.4%, 85.3%, and 100.0% in stages I, II, III, and IV, respectively. STELLA also detected 5 of 15 in situ carcinomas, corresponding to a sensitivity of 33.3%. Across molecular subtypes, sensitivity was highest in HR+/HER2+ disease at 89.9%, followed by HR−/HER2− at 81.4%, HR−/HER2+ at 79.5%, and HR+/HER2− at 51.6%.


Among patients classified as BI-RADS category 4 on ultrasound, mammography, or MRI, STELLA demonstrated sensitivities of 55.5%, 59.7%, and 63.3%, respectively, with corresponding specificities of 98.3%, 100.0%, and 95.0%.


These findings highlight STELLA’s potential as an adjunctive tool for differentiating benign and malignant breast lesions. Its high specificity may support its use alongside conventional imaging to help identify a subset of BI-RADS category 4 patients with a high probability of malignancy. Given the lower tumor burden in early-stage disease, a negative result alone cannot rule out malignancy; assessment should integrate follow-up imaging and pathological examination. The research team will also incorporate follow-up data to further explore STELLA’s potential prognostic value in patients with breast cancer.

Learn More
January 03, 2023
Burning Rock Received FDA Breakthrough Device Designation for its OverC™ Multi-Cancer Detection Blood Test
Learn More
June 01, 2022
Burning Rock Receives CE Mark for its OverC™ Multi-Cancer Detection Blood Test Kit
Learn More
June 01, 2022
Burning Rock Announces the Launch of China's First Prospective Interventional Validation Study on Multi-Cancer Early Detection - the PREVENT Study
Learn More
June 01, 2022
Burning Rock Receives CE Mark Approval for Three NGS Tumor Kits
Learn More
March 15, 2022
Burning Rock Secures Second NGS Kit Approval from the NMPA
Learn More
November 17, 2021
Merck KGaA, Darmstadt, Germany and Burning Rock Collaborate on Liquid-biopsy Based CDx Development Using Burning Rock's OncoCompass™ Target
Learn More
August 03, 2021
Burning Rock and IMPACT Therapeutics Announce a Global Strategic Partnership for Companion Diagnostics Development
Learn More
April 29, 2021
Burning Rock and Abbisko Therapeutics Announce Strategic Partnership on Co-development of Companion Diagnostics for ABSK091
Learn More
June 29, 2020
Burning Rock and CStone Pharmaceuticals reached a strategic collaboration on the co-development of companion diagnostics for pralsetinib in China
Learn More
1 2 3 4
Contact Our Experts
We would like to collect certain personal information about you through cookies and similar technologies in order to personalize the site for you, improve the performance of the site, and support our marketing efforts. By clicking “Accept All”, you confirm that we have your consent to collect and process your personal information in accordance with our Privacy Policy, which may include online targeted and social media advertising in some instances. You can by clicking “Reject All”, you can reject all cookies except for Strictly Necessary Cookies."